Eli Lilly and Co
Patients regain weight after stopping Eli Lilly's Zepbound, study says
Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took Eli Lilly‘s weight loss drug Zepbound regained around half the weight they shed after stopping the newly approved treatment for a year, according to data released Monday. The data, which represents the full results from an […]
Read More
Treasury yields inch increased in advance of Fed meeting
U.S. Treasury yields have been fractionally better on Monday, as investors appear ahead to this week’s Federal Reserve policy meeting. The yield on the benchmark 10-calendar year Treasury observe was just in excess of a solitary foundation stage higher at 4.2563%, although the produce on the 30-yr Treasury bond was just underneath a level greater […]
Read More
Investing in Space: Why Amazon bought rocket launches from rival SpaceX
United Launch Alliance Atlas V rocket carrying the first two demonstration satellites for Amazon’s Project Kuiper broadband internet constellation stands ready for launch on pad 41 at Cape Canaveral Space Force Station on October 5, 2023 in Cape Canaveral, Florida, United States. Paul Hennessey | Anadolu Agency | Getty Images CNBC’s Investing in Space newsletter […]
Read More
Biden administration asserts ability to seize drug patents in shift to slash significant charges
President Joe Biden speaks about guarding Social Protection, Medicare, and lowering prescription drug expenditures, during a stop by to OB Johnson Park and Local community Centre, in Hallandale Beach front, Florida, on Nov. 1, 2022. Kevin Lamarque | Reuters The Biden administration on Thursday asserted its authority to seize the patents of sure highly-priced prescription […]
Read More
Five stocks to acquire just before the year finish, according to the professionals
Quite a few shares have observed enormous rallies this year as buyers turned bullish on sectors like Big Tech, biotech, electric powered cars, and weight decline drugs. As the year-conclusion nears, CNBC Pro requested a few fund managers for sectors — and stocks — they are bullish on in the guide-up to 2024. In this […]
Read More
Eli Lilly vs. Novo Nordisk: The professionals supply their verdict on the viral body weight-reduction stocks
It has been really a calendar year for both Eli Lilly and Novo Nordisk given the increase in excess weight-reduction drugs. Stocks of both pharmaceutical corporations have rallied this 12 months. Shares in Eli Lilly are up all over 60% yr-to-date, while its Danish counterpart Novo Nordisk has noticed a achieve of about 50%. As […]
Read More
Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues. Zepbound is […]
Read More
December’s ‘best-in-class’ shares contain this weight problems beneficiary, Wall Road analysts say
An being overweight beneficiary and a snack foods company are just a several of the prime stocks to acquire in December, analysts reported this week. Wall Road investigate companies named a slew of corporations that they consider have upside heading into the years close. CNBC Pro combed by way of recent analyst notes to come […]
Read More
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More